Changchun High-Tech Industries (000661.SZ): Polyethylene Glycol Recombinant Human Growth Hormone Injection Approved for Additional Indications Supplement Application.

Changchun High-Tech Industries (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for a supplemental application for the recombinant human growth hormone injection (trade name: Jinsai Zeng) of polyethylene glycol. Specifically, the approved specifications for 54IU/9.0mg/1.0ml/bottle have been expanded to include the following indications that have already been approved in China: for growth disorders in girls with gonadal dysgenesis (Turner Syndrome); and for idiopathic short stature (ISS). The approved specifications for 27IU/4.5mg/0.5ml/bottle have been expanded to include the indication for slow growth in children caused by endogenous growth hormone deficiency.